Listen

Add to my selection

SOLIRIS

Medicine - Posted on May 17 2024

Active substance (DCI)

eculizumab

history (7)

4/24/24

SOLIRIS (eculizumab) - Myasthenia

Summary of opinion Unfavourable opinion for reimbursement in the treatment of refractory generalised myasthenia gravis (gMG)...

CAV :
54321

icône flèche
3/22/23

SOLIRIS (éculizumab) - Atypical haemolytic uraemic syndrome (aHUS)

Reassessment. Key points Favourable opinion on the maintenance of reimbursement in the “treatment of atypical haemolytic ura...

CAV :
54321

icône flèche
9/16/20

SOLIRIS

Key points Favourable opinion for reimbursement in the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult ...

CAV :
54321

icône flèche
6/27/18

SOLIRIS (eculizumab)

Le laboratoire ne demande pas le remboursement dans l’indication chez l’adulte pour le traitement de : Myasthénie acquise gé...

icône flèche
6/26/13

SOLIRIS (eculizumab)

SOLIRIS (eculizumab)

icône flèche
9/19/12

SOLIRIS

-

CAV :
54321

icône flèche

10/24/07

SOLIRIS (eculizumab)

SOLIRIS (eculizumab)

CAV :
54321

icône flèche

Technical information

ATC code

L04AJ01

Manufacturer

ALEXION PHARMA FRANCE

Presentation

SOLIRIS 300 mg, solution à diluer pour perfusion (code CIS : 61969188)
1 flacon en verre de 30 ml (CIP : 34009 571 138 4 1)

All our publications

Anemia and hemoglobinopathies

Autoimmune diseases

Blood coagulation and hemostasis disorders

Kidney diseases

Neuromuscular diseases